Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Designates First Czech Notified Body Under MDR

Executive Summary

The latest notified body listing brings total number of EU designated Medical Device Regulation testing and certification organizations to 35.

You may also be interested in...



Another Italian Notified Body Designated Under MDR

This new listing is the tenth Italian notified body under the Medical Device Regulation, bringing the total number of notified bodies to 36.

Yet Another Italian Notified Body Designated As EU Total Reaches 34

There are now nine notified bodies in Italy designated under the scope of the Medical Device Regulation and 34 in the EU in total.

One More EU MDR Notified Body In The Pipeline And Then A Gap

With major concerns persisting over notified body capacity under both the EU medical device and IVD regulations, every new designation is important. The numbers continue to nudge up slowly.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147375

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel